XTL Biopharmaceuticals Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XTLB research report →
Price Chart
About the company
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome.
- CEO
- Noam Band
- IPO
- 2005
- Employees
- 10
- HQ
- Herzliya, TA, IL
Get TickerSpark's AI analysis on XTLB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.61M
- P/E
- -0.88
- PEG
- 0.01
- P/S
- 0.00
- P/B
- -24.71
- EV/EBITDA
- -5.39
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -269.02%
- ROIC
- -11253.33%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-1,688,000
- Net Income
- $-6,969,000-578.6%
- EPS
- $-17.00-608.3%
- OCF Growth
- +36.7%
- FCF Growth
- +38.7%
- 52W High
- $10.28
- 52W Low
- $2.01
- 50D MA
- $2.76
- 200D MA
- $2.98
- Beta
- 0.46
- RSI (14)
- 48
- Avg Volume
- 73.97K
No earnings-call transcripts are available for XTLB yet.
- Free Float
- 97.5%
- Shares Outstanding
- 9.46M
- Float Shares
- 9.23M
of shares held by institutions
6 13F filers
Buy/sell ratio 0.18. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Noked Capital Ltd | 198.89K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Hillel Fain Osnat | other | 1,000,000 |
| Mar 18, 26 | Segal Niv | other | 0 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 24,681,360 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 2,696,450 |
| Nov 19, 08 | EDELMAN JOSEPH | sell | 9,600,000 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 29,740 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 400,000 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 1,943,250 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 400,000 |
| Nov 18, 08 | EDELMAN JOSEPH | sell | 299,570 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XTLB coverage
Recent articles, reports, and earnings notes.
No research on XTLB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XTLB report →XTL Biopharmaceuticals (NASDAQ:XTLB) Shares Pass Above Fifty Day Moving Average – Here’s Why
defenseworld.net · Aug 20
XTL Completed the Acquisition of Psyga Bio Ltd.
globenewswire.com · Jun 30
XTL Completed the Acquisition of Psyga Bio Ltd.
globenewswire.com · Jun 30
XTL Announces Receipt of Staff Delist Determination from Nasdaq
globenewswire.com · May 22
XTL Announces Receipt of Staff Delist Determination from Nasdaq
globenewswire.com · May 22
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
globenewswire.com · Apr 29
XTL Biopharmaceuticals Announces ADS Ratio Change
globenewswire.com · Mar 20
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
globenewswire.com · Feb 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.